Evidence map›Paper›PMID 41544143›Full record

ArticlePLoS neglected tropical diseases2026

Immune checkpoint TIM-3 defines hyperactivated NK cells and predicts fatal outcome in severe fever with thrombocytopenia syndrome.

Xiaohan Qian, Yi Zhang, Ziling Cheng, Haolin Song, Lingtong Huang, Bei Jia, Jie Li, Jie Wang, Wei Wu

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaohan QianState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yi ZhangDepartment of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ziling ChengState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Haolin SongState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lingtong HuangDepartment of Critical Care Units, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Bei JiaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Jie LiDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Jie WangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wei WuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0003-2892-5956

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere fever with thrombocytopenia syndrome (SFTS) is a viral hemorrhagic fever with high mortality, primarily driven by immune dysregulation. This study aimed to characterize the expression profile of TIM-3 expression on peripheral NK cells in SFTS, explore the role of TIM-3 ⁺ NK cells in disease progression, and evaluate soluble TIM-3 (sTIM-3) and Galectin-9 (sGalectin-9) as prognostic biomarkers.

methodsPublic single-cell RNA sequencing (scRNA-seq) datasets were analyzed using weighted gene co-expression network analysis (WGCNA). Peripheral blood samples from 21 SFTS patients and 14 healthy donors collected at the First Affiliated Hospital, Zhejiang University School of Medicine, were analyzed by flow cytometry, functional assays, and serological assessments. NK cell cytotoxicity was assessed by granzyme B, perforin, IFN-γ, and TNF-α production. Serum sTIM-3 and sGalectin-9 were measured by Cytometric Bead Array.

resultsTIM-3 ⁺ NK cells were significantly increased in SFTS patients, especially in fatal cases. WGCNA identified HAVCR2 (encoding TIM-3) as a mortality-associated hub gene. TIM-3 ⁺ NK cells exhibited enhanced granzyme B and perforin expression, while TIM-3 blockade significantly reduced IFN-γ and TNF-α production. Elevated sTIM-3 and sGalectin-9 levels were correlated with fatal outcomes.

conclusionsActivated TIM-3 ⁺ NK cells were associated with fatal outcomes in SFTS. TIM-3 ⁺ NK cell proportion, sTIM-3, and sGalectin-9 may serve as novel prognostic biomarkers and therapeutic targets.

Indexed as

Hepatitis A Virus Cellular Receptor 2Killer Cells, NaturalSevere Fever with Thrombocytopenia SyndromeAdultAgedBiomarkersFemaleGalectinsGranzymesHumansMaleMiddle AgedPerforinPrognosisBiomarkersGalectinsGranzymesHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2LGALS9 protein, humanPerforin

Identifiers

PMID41544143
PMCPMC12829940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.